Literature DB >> 22616753

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.

Krzysztof Flis1, David Irvine, Mhairi Copland, Ravi Bhatia, Tomasz Skorski.   

Abstract

The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP). Electron "leakage" from the MRC generates reactive oxygen species (ROS). Chronic myeloid leukemia in chronic phase (CML-CP) stem cells (LSCs) produce high levels of mitochondrial ROS, causing oxidative DNA damage, resulting in genomic instability, generating imatinib-resistant BCR-ABL1 kinase mutants and additional chromosomal aberrations. Using global mRNA microarray analysis combined with Ingenuity Pathway Analysis we found that LSCs display enhanced expression of genes encoding MRC complexes I, II, IV and V. However, expression of genes encoding complex III was deregulated. Treatment with imatinib did not correct the aberrant levels of MRC genes. Therefore we postulate that abnormal expression of MRC genes may facilitate electron "leakage" to promote the production of ROS and accumulation of genomic instability in LSCs in imatinib-naive and imatinib-treated patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22616753     DOI: 10.3109/10428194.2012.696313

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

Review 1.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

Review 2.  Deciphering Metabolic Adaptability of Leukemic Stem Cells.

Authors:  Sweta B Patel; Travis Nemkov; Angelo D'Alessandro; Robert S Welner
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 3.  Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.

Authors:  John Joson Ng; S Tiong Ong
Journal:  Curr Hematol Malig Rep       Date:  2022-10-19       Impact factor: 4.213

Review 4.  Targeting chronic myeloid leukemia stem cells.

Authors:  Ross Kinstrie; Mhairi Copland
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

5.  Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2.

Authors:  Marta E Capala; Henny Maat; Francesco Bonardi; Vincent van den Boom; Jeroen Kuipers; Edo Vellenga; Ben N G Giepmans; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

6.  Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.

Authors:  Jonathan M Gerber; Jessica L Gucwa; David Esopi; Meltem Gurel; Michael C Haffner; Milada Vala; William G Nelson; Richard J Jones; Srinivasan Yegnasubramanian
Journal:  Oncotarget       Date:  2013-05

7.  Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.

Authors:  L Truitt; C Hutchinson; J F DeCoteau; C R Geyer
Journal:  Oncogenesis       Date:  2014-10-20       Impact factor: 7.485

8.  A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies.

Authors:  Mary E Irwin; Blake P Johnson; Roxsan Manshouri; Hesham M Amin; Joya Chandra
Journal:  Oncotarget       Date:  2015-09-15

Review 9.  DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.

Authors:  Elzbieta Pawlowska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

10.  Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.

Authors:  Kamilla M E Laidlaw; Samuel Berhan; Suhu Liu; Giovannino Silvestri; Tessa L Holyoake; David A Frank; Bharat Aggarwal; Michael Y Bonner; Danilo Perrotti; Heather G Jørgensen; Jack L Arbiser
Journal:  Oncotarget       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.